Two Tales of Antioxidant Enzymes on β Cells and Diabetes

Xin Gen Lei and Marko Z. Vatamaniuk

Abstract

Pancreatic islets contain low activities of catalase, selenium-dependent glutathione peroxidase 1 (GPX1), and Cu,Zn-superoxide dismutase 1 (SOD1). Thus, enhancing expression of these enzymes in islets has been unquestionably favored. However, such an attempt has produced variable metabolic outcomes. While β cell-specific overexpression of *Sod1* enhanced mouse resistance to streptozotocin-induced diabetes, the same manipulation of catalase aggravated onset of type 1 diabetes in nonobese diabetic mice. Global overexpression of *Gpx1* in mice induced type 2 diabetes-like phenotypes. Although knockouts of *Gpx1* and *Sod1* each alone or together decreased pancreatic β cell mass and plasma insulin concentrations, these knockouts improved body insulin sensitivity to different extents. Pancreatic duodenal homeobox 1, forkhead box A2, and uncoupling protein 2 are three key regulators of β cell mass, insulin synthesis, and glucose-stimulated insulin secretion. Phenotypes resulted from altering GPX1 and/or SOD1 were partly mediated through these factors, along with protein kinase B and c-jun terminal kinase. A shifted reactive oxygen species inhibition of protein tyrosine phosphatases in insulin signaling might be attributed to altered insulin sensitivity. Overall, metabolic roles of antioxidant enzymes in β cells and diabetes depend on body oxidative status and target functions. Revealing regulatory mechanisms for this type of dual role will help prevent potential pro-diabetic risk of antioxidant over-supplementation to humans. *Antioxid. Redox Signal.* 14, 489–503.

Introduction

MILLIONS OF PEOPLE in the United States and elsewhere suffer from type 1 diabetes and type 2 diabetes. In fact, type 2 diabetes is becoming an epidemic disease that afflicts 10%–25% of the population. Pathologically, type 1 diabetes is characterized by destruction of pancreatic islet β cells, loss of insulin synthesis, and failure of glycemic control. Its development is incited by genetic predisposition and environmental factors, including reactive oxygen species (ROS) or oxidative stress (102). Insulin resistance is a hallmark and a key factor in the pathogenesis of type 2 diabetes (28). Although development of overt type 2 diabetes from insulin-resistant state may take a long time due to an initial increase in islet β cell mass and(or) function, an eventual failure of this compensation leads to impaired β cell functions and body glucose homeostasis. The turning point and the underlying mechanism still remain a challenging question.

Earlier, ROS was implicated only in complications of type 2 diabetes. However, evidence has been accumulated for a causal role of oxidative stress in inducing insulin resistance before the onset of diabetes (15). In cultured 3T3-L adipocytes (114) and L6 muscle cells (8), H_2O_2 decreased insulin-mediated glucose uptake, glycogen synthesis, Glut 4

transportation, and phosphorylation of insulin signaling proteins. In humans, oxidative stress has been shown to be associated with adiposity and insulin resistance (62). Likewise, ROS production in adipose tissue of obese mice was accompanied by augmented expression of NADPH oxidase and decreased expression of antioxidant enzymes (35). In skeletal muscle, oxidative stress caused substantial insulin resistance in distal insulin signaling and glucose transport activity (5). A recent genomic analysis of cytokine- and glucocorticoid-induced insulin resistance revealed a common role of ROS in developing this disorder (50). Because of those involvements of oxidative stress in both type 1 diabetes and type 2 diabetes, antioxidant enzymes and antioxidant nutrients have been thought to protect against diabetes. However, findings from a number of recent animal and human studies strongly challenge this prevailing paradigm.

Perceived Susceptibility of β Cells to Oxidative Stress

Like most living organisms on the Earth, mammals, including humans, use energy mainly produced by coupled reactions of respiration and oxidative phosphorylation in mitochondria. According to Mitchell's chemiosmotic theory, ATP synthesis links with mitochondrial membrane potential

(96). The system is reversible by uncouplers of respiration and oxidative phosphorylation such as 2,4-dinitrophenol. However, mitochondrial respiration generates not only ATP but also free radicals. Because those molecules have one or more unpaired electrons in certain atoms such as oxygen or nitrogen and usually seek other electrons to become paired, they are highly reactive or destructive to attack other molecules. Hydroxyl radical, superoxide, and hydrogen and lipid peroxides are often considered to be main forms of metabolically derived ROS. Nitric oxide and peroxynitrite are the main forms of reactive nitrogen species (RNS). Despite recent discovery of dual roles of H_2O_2 derived from glucose metabolism in insulin secretion and β cell integrity (108), ROS and RNS have been largely perceived to be detrimental to β cells and insulin function.

Mammals have evolved with three cellular antioxidant defense systems to cope with ROS and RNS. These include (a) low-molecular-mass antioxidants such as GSH, uric acid, and vitamins C and E; (b) antioxidant enzymes; and (c) sequestration and repairing systems. Although all three protective systems are important and interdependent, this review focuses on only antioxidant enzymes. As widely accepted, catalase, glutathione peroxidase (GPX), and superoxide dismutase (SOD) represent the three most important intracellular antioxidant enzymes. Among the six forms of selenium (Se)-dependent GPX, GPX1 was the first identified and most abundant selenoprotein. Located in both cytosol and mitochondria (26), GPX1 accounts for over 90% of the total GPX activity in most tissues (19), and utilizes GSH to reduce H_2O_2 and other organic hydroperoxides. Due to this biochemical function, GPX1 was initially considered to be a major intracellular antioxidant enzyme *in vivo*. Later, that presumed function was questioned because of its high tissue abundance, extreme responsiveness to Se supply, and low ranking in acquiring Se in Se deficiency (125). Recent research using the *Gpx1* knockout (*Gpx1*^{-/-}) and overexpressing *Gpx1* (OE) mice

has demonstrated that normal *Gpx1* expression is essential, and overexpression of *Gpx1* is beneficial for protection against acute oxidative stress induced by ROS (20). However, GPX1 actually potentiates toxicities of drugs that induce formation of peroxynitrite (34, 95). There are three forms of SOD: SOD1, Cu,Zn-SOD; SOD2, Mn-SOD; and SOD3, extracellular SOD3. SOD1 comprises over 90% of the total cellular SOD activity, and functions upstream of GPX1 in catalyzing dismutation of $O_2^{\bullet-}$ into H_2O_2 . Likewise, knockout of *Sod1* alone or together with *Gpx1* actually protected mice against acetaminophen-induced lethality and hepatic protein nitration (146). Catalase shares a common substrate of H_2O_2 with GPX1, but with a higher *km*. In addition, glutathione reductase, thiodoxin reductase, and glutathione S-transferase are also detected in islets.

Pancreatic islets of Langerhans represent a main structure to regulate glucose metabolism and homeostasis. Representing the major portion of islets, β cells synthesize and secrete insulin. There are also three other types of endocrine cells to produce three different hormones, respectively (Fig. 1). Compared with liver, islets contain only 1% catalase, 2% GPX1, and 29% SOD1 activities (40, 80, 130). Thus, β cells are considered to be low in antioxidant defense and susceptible to oxidative stress. Significant differences in allele and genotype distribution in *Sod1* and *Sod2* genes (but not in catalase gene) were found among type 1 diabetes, type 2 diabetes, and control subjects (33). In a large Japanese cohort, GPX1 Pro198Leu variant was found to contribute to the metabolic syndrome in men, but not in women (74). Earlier work in the 1990s showed that loss of pancreatic GPX activity was often associated with islet dysfunction (6). In fact, β cells are a primary target of diabetogenic agents streptozotocin (STZ) and alloxan that generates H_2O_2 (84, 126). Loss of β cell mass has been recognized as a pivotal factor in pathogenesis of type 2 diabetes (109). Most individuals with type 2 diabetes show a net decrease of β cell mass, whereas obese individuals who

FIG. 1. Overview of endocrine cell types and functions, main forms of ROS and RNS, and antioxidant defense systems in pancreatic islets. The tilted balance scale symbolizes a perceived susceptibility of β cells to ROS or oxidative stress due to relatively low activity of antioxidant enzymes. RNS, reactive nitrogen species; ROS, reactive oxygen species.

develop insulin resistance but not type 2 diabetes exhibit an increased β cell mass for the compensatory insulin synthesis and secretion (13). Pancreatic β cell mass is primarily regulated by replication and apoptosis (109). Transcriptional factors pancreatic duodenal homeobox 1 (PDX1) plays a pivotal role in proliferation, survival, and function of β cells and activation of insulin gene expression (3, 145). Meanwhile, β cell apoptosis in diabetic subjects is a more deciding factor than replication compared with control subjects (13). This event can be triggered by high glucose (30) and cytokines that induce ROS and RNS formations (91).

The well-known harmful effect of hyperglycemia or glucose toxicity has long been recognized to be mediated by oxidative stress. Exposure of RIN 1046-38 β cells with increased glucokinase activity to 20 mM glucose resulted in decreases of NADP(H) and ATP levels, accumulation of ROS, damages of mitochondria and DNA, and apoptosis (140). A superoxide-related pathway was proposed to account for ATP decreases in hyperinsulinemia-induced β cell dysfunction (69). However, exposing β cells isolated from rat to 20 mM glucose did not increase H_2O_2 or superoxide production, but led to a dose-dependent increase in NADP(H) and $FADH_2$ levels (92). Treating the RIN 1046-38 β cells with normal glucokinase activity with high glucose failed to induce excessive ROS production (140). These discrepancies underscore functional complexity of ROS and antioxidant enzymes in β cell integrity and glucose metabolism.

Crucial Roles of PDX1 and Forkhead Box A2 in β cells and Insulin Synthesis

Pancreatic duodenal homeobox 1

Discovered in 1993 as a regulator of insulin and somatostatin promoters (81), PDX1 (IPF1 in humans) has been shown to be responsible for defective insulin secretion and development of maturity onset type of diabetes (MODY 4) (120, 121). It is a key factor in defining the fate of exocrine and endocrine pancreas development, and plays a pivotal role in pancreatic β cell differentiation and insulin gene expression (3, 56, 120). Insulin is synthesized in significant quantities only in islet β cells, and its mRNA is translated as a single chain precursor called preproinsulin. After removal of the signal peptide and entering the endoplasmic reticulum, pro-insulin is produced for secretion. In the process of insulin gene expression, PDX1 binds to the insulin promoter at three sites: A1, A3, and A5. Under glucose toxicity, *Pdx1* gene expression is inhibited by posttranscriptional defect and distorted binding of PDX1 protein to the insulin gene promoter (112). In addition, PDX1 regulates expression of hundreds of other genes related to glucose metabolism. Using promoter microarrays, Keller and associates identified 583 new PDX1 target genes (65). A close analysis of 31 proteins encoded by these PDX1 target genes indicated that 29 of those were expressed in β cells, and 68% of which was up- or downregulated by dominant negative mutation in *Pdx1* (65).

PDX1 plays an important role in β cell proliferation, neogenesis, and apoptosis. In C57BL/6 mice, a 60% pancreatectomy resulted in a progressive β cell mass increase within 2 weeks, and the increase was correlated with activation of *Pdx1* expression (107). Similarly, β cell mass or islet number in *Pdx1*^{+/-} mice failed to increase with age, and became 50% less

than the wild type (WT) at 1 year old (54). Clearly, loss of *Pdx1* expression is associated with increased apoptosis and decreased regeneration of progressive β cells. Islets and dispersed β cells from *Pdx1*^{+/-} mice were more susceptible to apoptosis at baseline glucose concentrations than those of *Pdx1*^{+/+}. An increased apoptosis *in vivo* in these mice was associated with abnormal islet architecture, positive TUNEL, active caspase-3, and lymphocyte infiltration (54). Moreover, pro-survival effects of insulin largely disappeared in islets with 50% PDX1 deficiency, which provided direct evidence that PDX1 was a signaling target of insulin (53). In rodent models of pancreatic injury, *Pdx1* expression was related to β cell neogenesis (116). Upregulation of PDX1 by a glucagon-like peptide 1 analog exendin-4 was followed by islet proliferation and islet to ductal transdifferentiation in partially pancreatectomized rats (29). PDX1 inhibits expression of glucagon gene that is mainly expressed in islet α cells, implying a cross control by a molecule from a different type of cells (49).

PDX1 also plays a crucial role in functioning of adult pancreas. It remains active in mature β cells through adulthood (103). In adult subjects, PDX1 is essential for normal pancreatic islet function by regulating expression of a number of pancreatic genes, including insulin, somatostatin, islet amyloid polypeptide, glucose transporter type 2, and glucokinase (51). Mice with 50% PDX1 had worsening glucose tolerance with age and reduced insulin release in response to glucose, KCl, and arginine from the perfused pancreas (54). Transcription of *Pdx1* in mice was reversibly repressed by administration of doxycycline, and the resultant impairments in insulin and glucagon expression led to diabetes within 14 days (49). However, withdrawal of doxycycline de-repressed *Pdx1* expression and restored normoglycemia within 28 days. Most importantly, ROS or oxidative stress affects expression and function of *Pdx1* at epigenetic, transcriptional, and post-translational levels (see below).

Forkhead box A2

Previously known as HNF3 β , forkhead box A2 (FOXA2) is an extremely important transcriptional factor from the Fox gene family that contains more than 40 conserved proteins with DNA-binding domain called forkhead box (57). These proteins are involved in organogenesis and regulation of multiple functions in adulthood. One of the most important functions for FOXA2 is to activate insulin gene expression by binding to the *Pdx1* promoter (77). It also controls vesicle docking and insulin secretion in mature β cells (37). Simultaneous ablation of *Foxa2* with *Foxa1* that cooccupies regulatory sites of *Pdx1* completely blocked *Pdx1* expression (36). A pancreas-specific ablation of *Foxa2* led to deregulated insulin secretion and hyperinsulinemic hypoglycemia (124). A FOXA ortholog (PHA-4) was involved in diet restriction-mediated longevity in *C. elegans* (105). At the same time, FOXA2 was also noticed as a regulator of insulin sensitivity as well as hepatic lipid metabolism and ketogenesis in fasting state and type 2 diabetes (138, 144). Reduced, oxidized, or total hepatic glutathione concentrations were decreased in *Foxa2* mutant mice fed a cholic acid diet compared with the WT controls (11). The *Sod1* promoter contains four consensus PHA-4 (FOXA) binding sites (14), and knockout of *Sod1* down-regulated *Foxa2* expression and function (see below).

Uncoupling Protein 2 and Mitochondria in Glucose-Stimulated Insulin Secretion

Classic scheme of glucose-stimulated insulin secretion (GSIS) depends on a high ATP/ADP ratio in β cells by glucose oxidation (143). Glucose metabolism in islets starts at glucose uptake by GLUT2, followed by the glucokinase-mediated phosphorylation and oxidation to produce ATP. The generated ATP molecules first bind to the ATP-binding cassette of SUR1 subunit of K_{ATP} -dependent potassium channels, and then cause closing of its second subunit potassium inward rectifier channels (KIR6.2). Consequently, intracellular concentration of potassium ions is increased followed by cell membrane depolarization and opening of voltage-dependent calcium channels. The resultant inward Ca^{2+} flux triggers in exocytosis of stored insulin. As a natural uncoupler of respiration and oxidative phosphorylation, uncoupling protein 2 (UCP2) is expressed in islet β cells (38) and is considered to be a negative regulator of insulin release (143). UCP2 is activated by endogenously produced superoxide (69) and can in turn modulate mitochondrial generation of H_2O_2 (100). Thus, UCP2 may serve as a link between intracellular oxidant/antioxidant balance to mitochondrial potential, ATP synthesis, and insulin secretion.

Mitochondrial dysfunction has been postulated to be a key factor in the development of type 2 diabetes. Defective GSIS and reduced β cell mass were seen in patients with mitochondrial dysfunction and in a relevant mouse model (137). A study using mice with dominant-negative IGF-1 receptor mutations in skeletal muscles (32) unveiled two-stage mechanisms for their gradually developed deterioration of mitochondrial functions and insulin resistance-induced β -cell failure. At the first 3 weeks of insulin resistant stage, there were abrogated hyperpolarization of mitochondrial membrane potential, reduced mitochondrial Ca^{2+} uptake, slightly enlarged mitochondria, and attenuated GSIS. At the onset of diabetes (the 10th week), hyperglycemia and hyperinsulinemia were developed with swollen mitochondria containing disordered cristae, reduced hyper-polarization of mitochondrial potential, impaired Ca^{2+} -signaling, and diminished glucose-stimulated production of ATP/ADP and insulin release. In diabetic islets, expression of 36 mitochondrial proteins, including inner membrane proteins of electron transport chain, was altered (90).

Desired Outcomes of Antioxidant Enzymes

Two lines of existing data or perceived views render up-regulating antioxidant defense in islets as a strategic treatment of diabetes or insulin resistance. The first is the predicted susceptibility of β cells to oxidative stress as mentioned above. The second is the responsiveness of key regulators of β cells and insulin, including PDX1, FOXA2, and UCP2 to ROS (12, 61, 63). Indeed, ROS-induced impaired insulin synthesis or secretion in insulin-producing or -secreting cells was partially alleviated by overproduction of GPX1, SOD1, and catalase (88, 131, 141). Enhancing expression of *Gpx1* and/or *Sod1* up to twofold protected NIT-1 mouse insulinoma cells from H_2O_2 and menadione, but only the *Gpx1* overexpression increased the cell survival after hypoxia reoxygenation (82). Protection of rat-derived insulin-secreting INS-1 cells against both ROS and RNS resulted from an adenoviral-mediated *Gpx1* overexpression (97). While cytoplasmic catalase overexpression in insulin-producing RINm5F cells provided stronger protection

against H_2O_2 toxicity, only mitochondrial overexpression of this enzyme in these cells provided protection against menadione that preferentially generates superoxide radicals in mitochondria (42). The mitochondrial catalase overexpression was also preferentially protective against toxicity of interleukin-1 β and a pro-inflammatory cytokine mixture. In another study with the same cell line, overexpression of *catalase*, *Gpx1*, and *Sod1* conferred protection against toxicity of the cytokine mixture (interleukin-1 β , tumor necrosis factor- α , and γ -interferon) but not that of interleukin-1 β alone (89).

Adenoviral overexpression of glutathione-related enzymes in pancreatic islets can prevent oxidative stress-induced insulin loss (113). The glucose- or ribose-induced islet peroxide accumulation and the adverse consequences of insulin mRNA, content, and secretion were aggravated by a GSH synthesis inhibitor, but alleviated by increasing islet GPX1 activity (127). After isolate islets were transferred with *Sod2* gene by adenoviral infection and transplanted into STZ-treated nonobese diabetic (NOD) mice, these islets functioned 50% longer than the control ones (7). When islets from transgenic mice cooverexpressing human *Sod1*, *Sod3*, and/or *Gpx1* were exposed to hypoxanthine/xanthine oxidase treatment *in vitro*, relative resistance was in the following order: [SOD1 + SOD3 + GPX1] > [SOD3 + GPX1] > [SOD3] > WT (99). However, overexpression of all three enzymes in combination was required to display a protection against hypoxia/reoxygenation or an improvement in blood glucose in STZ-treated recipient mice transplanted with the transgenic islet grafts. When islets from mice with β cell-specific overexpression of metallothionein up to 30-fold were exposed to STZ *in vitro*, they exhibited much less islet disruption, DNA breakage, and depletion of NAD^+ (16). Meanwhile, an overexpression of thioredoxin in islets prolonged graft survival in autoimmune diabetic NOD mice (21). This improvement resembled effects of intraperitoneal injections of oleanic acid on graft-specific immune response.

Studies using diabetic models showed improved insulin sensitivity by antioxidants, including lipoic acid (52). Improved insulin sensitivity was also seen in insulin-resistant and/or diabetic patients by treating them with antioxidant vitamins (28). Further, injections of an analog of antioxidant probucol prevented type 1 diabetes in NOD and multiple low doses-STZ mice models (55). An earlier study (111) showed that SOD (105 mU/g) administered intravenously to rats 50 min before STZ intravenous injection (45 mg/kg) abolished the STZ-induced pancreatic insulin decrease and glucose intolerance. It is clinically relevant that induced expression of *Gpx3* was required for the regulation of peroxisome proliferator-activated receptor gamma (PPARgamma)-mediated antioxidant effects produced by thiazolidinediones, a PPARgamma agonist used to improve insulin sensitivity in treating type 2 diabetes (22). In cultured cells with ROS-induced insulin resistance, six treatments designed to modulate ROS status, including two small molecules and four transgenes of *cyto-catalase*, *mito-catalase*, *Sod1*, and *Sod2*, ameliorated insulin resistance to various extents. A chronic treatment of leptin-deficient *ob/ob* obese, insulin-resistant mice with antioxidant manganese (III) tetrakis (4-benzoic acid) porphyrin (MnTBAP) and insulin-sensitizing drug rosiglitazone improved insulin sensitivity and glucose homeostasis (50).

Table 1 depicts main metabolic impacts or phenotypes associated with overexpressing seven common antioxidant

enzymes/proteins. Transgenic mice with β cell-specific overexpression of metallothionein were protected from the STZ-induced hyperglycemia, degranulation, and cell death (16). Global overexpression of *Sod1* in mice enhanced their resis-

tance to type 1 diabetes induced by alloxan (71). Global or β cell-specific overexpression of *Sod1* in NOD mice enhanced their resistance to alloxan-induced diabetes (70, 71). A similar positive effect of *Sod1* overexpression in liver of *db/db* mice

TABLE 1. SUMMARY OF MAJOR METABOLIC IMPACT AND PHENOTYPE RESULTED FROM GLOBAL OR TISSUE (β CELL AND LIVER)-SPECIFIC OVEREXPRESSION AND GLOBAL KNOCKOUT OF SEVEN COMMON ANTIOXIDANT ENZYMES/PROTEINS IN MICE

Gene	Phenotype	Source
Transgenic (overexpression)		
Catalase (β -cell specific)	Protection of islet insulin secretion against H_2O_2 and significantly decreased diabetogenic effect of STZ <i>in vivo</i> ; no protection against interleukin-1 β toxicity or altering effects of syngeneic and allogenic transplantation on islet insulin content	Xu <i>et al.</i> (141)
GPX1 (global)	Development of hyperglycemia, hyperinsulinemia, increased β -cell mass, hypersecretion of insulin, insulin resistance, and obesity	McClung <i>et al.</i> (93), Wang <i>et al.</i> (136)
GPX1 (β -cell specific)	Protection against STZ, reversing hyperglycemia in <i>db/db</i> mice, and improving β -cell volume and granulation	Harmon <i>et al.</i> (43)
GPX1, SOD1, and SOD3 (global)	Protection of islets against hypoxanthine/xanthine oxidase treatment <i>in vitro</i> in the following order: [SOD1 + SOD3 + GPX1] > [SOD3 + GPX1] > [SOD3] > WT; a protection against hypoxia/reoxygenation and an improvement in blood glucose in STZ-treated recipient mice transplanted with the transgenic islet grafts with overexpression of all three enzymes in combination	Mysore <i>et al.</i> (99)
Metallothionein (β -cell specific)	Protection of islets from STZ-induced disruption, DNA breakage, and depletion of NAD^+ ; Protection of mice from the STZ-induced hyperglycemia, and degranulation and cell death of islets	Chen <i>et al.</i> (16)
Metallothionein, catalase, and SOD2 (β -cell specific)	Accelerating diabetes after cyclophosphamide treatment and spontaneous diabetes in NOD male mice by overexpression of cytoplasmic catalase and methallothionein; no such effect of SOD2	Li <i>et al.</i> (83)
SOD1 (global)	Protection against type 1 diabetes-induced by alloxan	Kubisch <i>et al.</i> (71)
SOD1 (β -cell specific)	Protection against alloxan-induced diabetogenesis	Kubisch <i>et al.</i> (70)
SOD1 (liver specific)	Decreasing hepatic ROS and blood glucose level, and improving insulin sensitivity in <i>db/db</i> mice	Kumashiro <i>et al.</i> (72)
SOD2 (islets)	Extending islet function for 50% longer than that of the control after isolate islets were transferred with <i>Sod2</i> gene by adenoviral infection and transplanted into STZ-treated NOD mice	Bertera <i>et al.</i> (7)
SOD2 and catalase (β -cell specific)	Protection of islets against STZ and peroxynitrite, but not cytokine toxicity by the co-expression of both enzymes	Chen <i>et al.</i> (17)
SOD3 (β -cell specific)	No effect on diabetes onset and incidence in NOD mice	Sandstrom <i>et al.</i> (115)
Thioredoxin (islet)	Prolonging islet graft survival in autoimmune diabetic NOD mice	Chou and Sytwu (21)
Knockout		
Catalase	Sensitizing the mutant mice to alloxan-induced diabetogenesis, accelerated severe atrophy of pancreatic islets, and apoptosis; but not impact on STZ-induced diabetes	Kikumoto <i>et al.</i> (66)
GPX1	Enhancing mouse resistance to high-fat diet induced insulin resistance	Loh <i>et al.</i> (86)
GPX1	Decreasing pancreatic β -cell mass and plasma insulin concentration, mild pancreatitis	Wang <i>et al.</i> (135)
SOD1	Decreasing pancreatic β -cell mass, plasma insulin concentration, and body weight; mild hyperglycemia; attenuated glucose-stimulated insulin secretion; improved insulin sensitivity; mild pancreatitis	Wang <i>et al.</i> (135)
GPX1 + SOD1	Similar to the phenotypes of <i>Sod1</i> knockout	Wang <i>et al.</i> (135)

The list is derived as a representation instead of an exhausted record. Missing of any important models is solely due to authors' limited knowledge and manuscript length.

GPX1, glutathione peroxidase 1; NOD, nonobese diabetic; ROS, reactive oxygen species; SOD1, superoxide dismutase 1; STZ, streptozotocin; WT, wild type.

was also shown on hepatic ROS, blood glucose level, and insulin sensitivity (72). When *Gpx1* was specifically overexpressed in pancreatic β cells in C57BLKS/J mice, their β cells became resistant to multiple injection of STZ (43). After the transgene was introgressed into the pancreatic β cells of *db/db* mice, hyperglycemia, β cell volume, and insulin granulation and immune-staining were significantly improved.

Using a rat insulin promoter to direct pancreatic β cell-specific overexpression of catalase, Xu and associates (141) produced seven transgenic lines of mice sensitive to Friend leukemia virus B (FBV) with increased catalase activity in islets up to 50-fold. While the overproduced catalase activity had no detrimental effect on islet function, it conferred a remarkable protection of islet insulin secretion against H_2O_2 and significantly decreased diabetogenesis of STZ *in vivo*. A recent study using homozygous acatalase mice mutant has demonstrated similarly crucial role of catalase in protecting against alloxan-induced type 1 diabetes (66). Compared with WT controls, the mutant mice had a higher (72 vs. 32%) incidence of diabetes after intraperitoneal injection of 180 mg of alloxan/kg of body weight. This high dose of alloxan also accelerated severer atrophy of pancreatic islets, and induced greater apoptosis in pancreatic β cells in the acatalasemic mice than in the control mice.

Intriguing Metabolic Enigma

Not all transgenes of antioxidant enzymes or proteins confer a metabolic protection against all insults (Table 1). When a 50-fold β cell-specific overproduction of catalase activity in FVB mice clearly protected islet against H_2O_2 and STZ toxicity, it did not provide any protection against interleukin-1 β toxicity or alter effects of syngeneic and allogeneic transplantation on islet insulin content (141). It was very intriguing that lack of catalase did not induce any compensation of GPX or SOD activity in pancreas and did not affect mouse susceptibility to STZ (but to alloxan)-induced diabetes (66). Likewise, β cell-specific overexpression of either *Sod2* or *Sod3* in NOD mice did not affect incidence of spontaneous diabetes (83, 115). When insulin-producing RINm5F cells were stably transfected with the *Sod2* gene, their cell viability was not different from the control or cells transfected with antisense of the *Sod2* gene after exposure to H_2O_2 or hypoxanthine/xanthine oxidase (87). However, overexpression of *Sod2* in these cells actually rendered them more susceptible to proinflammatory cytokine-induced decreases in viability and proliferation rate. In contrast, suppressing *Sod2* expression enabled the cells more resistant to this type of cytokine toxicity. Thus, altering mitochondrial balance between superoxide- and H_2O_2 -scavenging activities may constitute a greater cell vulnerability to cytokines. In addition, islets isolated from transgenic mice with coexpression of *Sod2* and *catalase* in β cells were not more resistant to cytokine toxicity than the controls, despite a clear advantage in coping with STZ and peroxynitrite (17).

Most striking, two independent studies have shown severe and long-term metabolic disorders associated with antioxidant enzyme transgenes. First, β cell-specific overexpression of cytoplasmic catalase and methallothionein greatly accelerated diabetes after cyclophosphamide treatment and spontaneous diabetes in NOD male mice, despite a protection against the cytokine-induced ROS production by both anti-

oxidant proteins and a decrease in the STZ-induced diabetes in the metallothionein transgenic mice (83). Second, mice OE developed hyperglycemia, hyperinsulinemia, insulin resistance, and obesity at 6 months of age (93). With a 20-fold increase in GPX1 activity, the OE islets were featured by ROS diminishing, but elevated β cell mass, insulin production, and GSIS (136). Diet restriction removed all of these type 2 diabetes phenotypes except for hyperinsulinemia and hypersecretion of insulin (136) (Fig. 2).

Comparatively, only overexpression of *Gpx1* elevated β cell mass, insulin production, and GSIS (136). In contrast, overproducing metallothionein and catalase in β cells actually accelerated the cytokine-induced β cell death (83). Seemingly, the positive effect of GPX1 on β cell mass and insulin production is not shared by other antioxidant proteins. This is because baselines of insulin concentration or insulin gene expression in islets were not altered by overexpressing catalase up to 50-fold (141) (83), metallothionein up to 30-fold (16, 83), or three forms of SOD enzymes up to 10-fold (17, 99). Although infection of rat islets with adenovirus encoding human *Gpx1* gene resulted in protections against the ribose-induced loss of insulin mRNA, content, and secretion, baseline levels of these three measures were unaltered (127). The relatively low (sixfold) increase in GPX1 activity in islets might be insufficient to induce significant elevation in baseline insulin synthesis or the 72 h infection of rat islets did not allow an illustration of GPX1 overexpression benefit to β cell mass.

Reciprocally, knockout of *Gpx1* enhances body resistance to high-fat diet-induced insulin resistance (86) (Table 1). Although knockouts of *Gpx1* and *Sod1* each alone or in combination resulted in similar decreases in pancreatic β cell mass and plasma insulin concentration, metabolic pathways for inducing their phenotypes are distinctly different (135). Further, the *Sod1* knockout (*Sod1*^{-/-}) mice developed more typical type 1 diabetes phenotypes than the *Gpx1*^{-/-} mice.

FIG. 2. Scheme of *Gpx1* overexpression leading to chronic hyperinsulinemia. ↑, Activation or increase; ↓, inhibition or decrease; ↓, decrease; P, phosphorylation. AKT, protein kinase B; FOXA2, forkhead box A2; GPX1, glutathione peroxidase 1; GSIS, glucose-stimulated insulin secretion; PDX1, pancreatic duodenal homeobox 1; PTP, protein tyrosine phosphatase; PTP-1B, protein tyrosine phosphatase-1B; UCP2, uncoupling protein 2.

Compared with the WT, the *Sod1*^{-/-} mice exhibited reduced body weight, hypoinsulinemia, blocked GSIS, hyperglycemia, and enhanced insulin sensitivity, along with elevated blood ketone bodies and urine glucose, pancreatitis, increased bone deterioration (134), and eye problems (44, 104). In comparison, the *Gpx1*^{-/-} mice developed only moderate hyperglycemia and showed no body weight change over the WT. However, these *Gpx1*^{-/-} mice were more sensitive to the cerulein-induced increase in serum amylase. Overall, knockout of *Sod1* exerted a more potent impact on islet function and pancreatic integrity than that of *Gpx1*. Outcomes of double knockout of both enzymes resembled those of *Sod1* knockout. Just as implicated in the cell case with mitochondrial catalase transfection (87), altering intracellular superoxide tone was probably more detrimental than that of hydroperoxides to insulin function and glucose metabolism. When type 1 diabetes was induced by alloxan in female WT, *Sod1*^{-/-}, and *Sod1* overexpressing mice before pregnancy, blood glucose concentrations and fetuses hepatic isoprostane levels were actually lower on the *Sod1*^{-/-} mice than in the other two groups (142).

Potential Risk of Human Health

Despite observed or perceived benefits of antioxidant enzymes or nutrients to diabetes (27, 46, 132), a potential risk associated with this notion has emerged (98). Increased erythrocyte GPX1 activity is strongly correlated with insulin resistance in gestational diabetic women (18). Most notably, at least eight major human studies have shown that Se supplements may be hyperglycemic, hyperlipidemic, and pro-diabetic. Adverse blood glucose and lipid profiles were seen in the U.S. and European adults with high plasma Se status (9, 10, 23, 75, 76, 122). Supplementing Se at 200 µg daily for 7.4 years to Se-adequate and initially nondiabetic old males enhanced their type 2 diabetes incidence by 50% (123). In particular, those subjects in the highest tertile of baseline plasma Se level displayed a hazard ratio of 2.7. Partially due to this increased risk potential, the planned 12-year Se and Vitamin E Cancer Prevention Trial (SELCT) was prematurely stopped in October 2008 (85).

Obviously, roles and mechanisms of antioxidant enzymes or nutrients in diabetes are far from clear. Paradoxically, antioxidant supplementation offsets health-promoting benefit of physical exercise in humans (110). Many past studies have overly amplified their transient benefits against a bolus of ROS, but neglected long-term metabolic consequences of shifting cellular redox status. In addition, antioxidant benefits to diabetic patient treatments may not be extrapolated to normal subjects for preventive purposes.

Novel Epigenetic Regulation of PDX1 by Antioxidant Enzymes

Because of the importance of PDX1 in controlling pancreatic β cell differentiation, survival, and insulin synthesis and its responsiveness to ROS, we have explored novel epigenetic regulations of PDX1 for explanation to the β cell and insulin phenotypes in mice with altered GPX1 and SOD1. Hyperinsulinemia and hypertrophy of β cell mass in the *Gpx1* overexpressing mice concurred with an elevated levels of H3 and H4 acetylation in the proximal region of promoter in pancreatic islets (136). Meanwhile, islets from these mice were

more resistant to H₂O₂-induced H3 and H4 hypoacetylation and had greater Pdx1 mRNA and protein levels than the WT islets (Fig. 2). In contrast, decreased β cells mass and plasma insulin concentration in mice with single knockout of SOD1 or double knockouts of *Gpx1* and *Sod1* was coincided with a declined H3 acetylation and H3K4 methylation in the *Pdx1* promoter region. Such changes were also correlated to decreases of *Pdx1* mRNA and protein (106).

Plasticity of chromatin is well known to be governed by multisubunit protein complexes that regulate chromosomal structure and activity (48). Such complexes include ATP-dependent chromatin remodeling factors that are involved in many fundamental processes, including DNA replication, transcription, and repairing as well as chromosome structure maintenance (48). The proximal region of *Pdx1* promoter consists of an islet-specific expression consensus E-box motif, which predominantly binds the upstream transcription factor (117). Site-specific acetylation or deacetylation of nucleosomal histone H3 and H4 is central to the switch between permissive and repressive chromatin structure and thus activation or repression of transcription (24). With a high affinity for upstream transcription factor binding (133), H3 and H4 are the core histones with high levels of acetylation at the active transcriptional loci (128). Preceding transcriptional activation (78), hyperacetylation of H3 and H4 helps remodel the chromatin in the *Pdx1* promoter to form more accessible structure for transcription (101). Thus, hyperacetylation of H3 and H4 in the OE islets should help in activating and hypoacetylation of H3 in the *Sod1*^{-/-} and double knockout of *Gpx1* and *Sod1* islets in suppressing *Pdx1* gene transcription. These distinct epigenetic regulations might partially explain their opposite changes in islet *Pdx1* mRNA expression. Lowering intracellular ROS by overproduction of GPX1 activity enhanced H3 and H4 acetylation, which allowed the OE mice to maintain a high level of functional PDX1 protein to promote β cell differentiation and insulin synthesis for compensating insulin resistance in these obese animals, so overt diabetes was avoided (136).

Another possible class of epigenetic regulations of *Pdx1* is DNA methylation. This modification takes place at the C5 position of cytosine, and is catalyzed by DNA methyltransferases (118). The methylation status of CpG islands within promoter sequences serves as an essential regulatory element in modifying the binding affinity of transcription factors to DNA binding sites. While most CpG islands remain unmethylated in normal cells, they may be methylated *de novo* under some circumstances. Despite unclear impacts of antioxidant enzymes on *Pdx1* methylation, relevance of this epigenetic regulation has been well demonstrated. A recent study indicated that *Pdx1* was 1 of only 15 CpG genes among 1749 examined ones with CpG islands that were methylation susceptible when methylation was upregulated by overexpression of a DNA methyltransferase (31). Development of type 2 diabetes in rats with intrauterine growth retardation was associated with progressive epigenetic silencing of *Pdx1*, in which methylation of the CpG island in the proximal promoter led to permanent silence of the *Pdx1* locus after the onset of diabetes in adulthood (106). Apparently, it will be fruitful to study how antioxidant enzyme overexpression or knockout affects methylation of *Pdx1* promoter and the subsequent impact on its function.

Regulation of Functional PDX1 Protein by Antioxidant Enzymes

Because PDX1 exerts its function mainly in nucleus, amount of functioning PDX1 protein at a given time depends on its transcription (mRNA), translation (protein), posttranslational modification (phosphorylation), and nucleocytoplasmic translocation of PDX1 (58). As mentioned above, OE mice had elevated levels of *Pdx1* mRNA and protein, along with attenuated PDX1 protein phosphorylation (degradation) in pancreatic islets (136) (Fig. 2). As a result, these mice maintained a greater level of functional PDX1 protein than the WT mice to produce hyperinsulinemia and hypertrophy of β cell mass. Supplementing C57BL/KsJ-*db/db* mice with dietary antioxidant nutrients produced similar positive effects on PDX1 protein (59). However, overexpression of catalase that shares the same substrate of hydrogen peroxide with GPX1 did not give such benefit, but accelerated the cytokine-induced PDX1 protein disappearance (83). Decreased β cell mass and plasma insulin concentration in mice with single and double knockouts of *Gpx1* and *Sod1* was accompanied by a declined pancreatic PDX1 protein (135) (Table 1 and Fig. 3).

Impacts of GPX1 overproduction on islet functional PDX1 protein may be mediated at multiple sites by ROS directly or indirectly through c-jun terminal kinase (JNK), protein kinase B (AKT), and protein tyrosine phosphatase-1B (PTP-1B) (63, 68, 73). Expression and function of these proteins are highly sensitive to ROS (39, 83, 94). Diminishing islet ROS by overproducing GPX1 could improve posttranslational stability of PDX1 protein. This is because hydrogen peroxide induces phosphorylation of PDX1 protein on ser⁶¹ and/or ser⁶⁶ (12), resulting in an increased degradation rate and decreased half-life of the protein. In fact, the ROS-diminished OE islets showed decreased phosphorylated and elevated total PDX1 protein (136) (Fig. 2). Meanwhile, hydrogen peroxide down-

regulates the DNA binding activity of PDX1 by inducing translocation of this protein from nucleus to cytoplasm (63). Lowering islet ROS should attenuate this event and allow more PDX1 protein to function in nucleus.

Knockout of *Sod1* elevated islet superoxide levels and decreased *Pdx1* mRNA and protein, contrary to the change in the OE mice (135). This implies a similar role of hydroperoxides and superoxide in regulating functional PDX1 protein. However, knockout of *Gpx1* actually elevated islet ROS (not superoxide) levels, but exerted no impact on *Pdx1* mRNA. Thus, either the induced changes in islet ROS were insufficient to affect *Pdx1* gene transcription, or the PDX1 protein decrease in the *Gpx1*^{-/-} was mainly attributed to accelerated protein phosphorylation (degradation) by the elevated H₂O₂ (12).

The attenuated ROS status in the OE mice decreased JNK activation (136). Inhibiting the JNK pathway protects β cells from glucose toxicity (60) and the oxidative stress induced-nuclear localization of forkhead transcription factor FOXO1 (64). FOXO1 was found to compete with FOXA2 for binding sites in the *Pdx1* promoter and thus suppressed *Pdx1* gene transcription in pancreatic β cells (68). Therefore, the overproduced GPX1 activity might enhance *Pdx1* transcription by repressing the JNK-FOXO1 pathway. In addition, suppression of phosphorylation of JNK also inhibits the ROS-induced nucleo-cytoplasmic translocation of PDX1 (63, 64). While the decreased AKT phosphorylation at Thr³⁰⁸ in the OE islets might attenuate the H₂O₂-mediated phosphorylation (degradation) of PDX1 protein (12), it could decrease phosphorylation of Foxo1 and then downregulates *Pdx1* transcription by the above-discussed mechanism (67, 68). The decrease of PTP-1B protein in the OE islets resembled the phenotype of PTP1-1B knockout mice (73). The improvement associated with β cell-specific overproduction of GPX1 in *db/db* mice was mediated by a reversed loss of v-maf musculoaponeurotic fibrosarcoma oncogene family protein A (MafA), which is another important transcriptional factor like PDX1 for β cells and insulin expression (43).

FIG. 3. Comparative impacts of *Gpx1* and *Sod1* knockouts on regulation of pancreatic islet FOXA2, PDX1, and β cell mass and function. ↓, Inhibition; SOD1^{-/-}, superoxide dismutase 1 knockout mice.

Superoxide-Dependent Regulation of Foxa2 by SOD1

As a key activator of *Pdx1* transcription, FOXA2 binds the promoter/enhancer of the *Pdx1* gene (139) and activates *Pdx1* gene expression *in vivo* (77). Because the *Sod1* promoter contains four binding sites for FOXA2 (105), and the mouse *Sod1* is indeed a transcriptional target of Foxa1 (14), illustrating a reciprocal effect of *Sod1* knockout on FOXA2 expression and function (Fig. 3) reveals a novel interdependence or positive feedback mechanism between these two proteins. The *Sod1* knockout caused an elevation of islet superoxide tone and resulted in substantial decreases in islet FOXA2 mRNA, protein, and binding to the *Pdx1* promoter (135). A direct link between the FOXA2 response and the SOD1 function was verified by treating WT and *Sod1*^{-/-} islets with the SOD1 enzyme inhibitor and mimic, respectively (135). Such a change was correlated to decreases of *Pdx1* mRNA and protein (106). In contrast, knockout of *Gpx1* elevated islet ROS but not superoxide levels, which exerted no impact on FOXA2 mRNA, protein, and its binding to the *Pdx1* promoter (135) (Fig. 3). Thus, effects of *Sod1* knockout on FOXA2 expression and binding function were superoxide dependent. Because of the distinct differences in regulating FOXA2 expression and function between the two H₂O₂- and superoxide-scavenging

enzymes (Fig. 3), adequate consideration should be given to metabolic subtlety of different forms of ROS in β cells and insulin function.

Regulation of UCP2 by Antioxidant Enzymes

Elevated GSIS in the OE mice might be explained by elevated islet mitochondrial potential and decreased UCP2 protein (136) (Fig. 2). Meanwhile, attenuated GSIS in the *Sod1*^{-/-} and *Gpx1*^{-/-} mice was consistent with decreases in islet ATP content and increases in UCP2 protein (135). Because UCP2 may be activated by endogenously produced superoxide (69) and can modulate mitochondrial generation of H₂O₂ (100), opposite responses of UCP2 induced by overexpression and knockout of *Gpx1* and/or *Sod1* may be interpreted as a metabolic compensation. A normal level of ROS in mitochondria is required for GSIS (79). Although a direct link of GPX1 function to islet UCP2 level was demonstrated by treating WT islets with a GPX1 mimic, ebselen (136), the sole UCP2 change may not fully explain a virtually blocked GSIS in *Sod1*^{-/-} but not *Gpx1*^{-/-} mice. A concurrent downregulation of other important regulators of GSIS (GLUT2, KIR6.2, and GLPR1) in the *Sod1*^{-/-} may offer additional explanations. Their alterations have been seen in insulin secretion disorders (4, 41, 119, 129).

Regulation of Insulin Signaling and Sensitivity by Antioxidant Enzymes

Because ROS has been shown to affect various steps of insulin signaling cascade starting from insulin receptor phosphorylation (45), impacts of antioxidant enzymes on body insulin sensitivity can be explained at least partially by their ability to modulate intracellular ROS status. The GPX1 overproduction-induced insulin resistance was associated with an attenuated phosphorylation of insulin receptor (β subunit) and AKT (Ser⁴⁷³ and Thr³⁰⁸) in liver and muscle (93) (Fig. 2). Earlier, a pro-insulin or insulin-mimic action of H₂O₂ on phosphorylation of β subunit of insulin receptor was shown in rat adipocytes (45). The action was not a direct effect

of hydrogen peroxide on the receptor, but mediated through downregulation PTP-1B, a negative regulator of insulin signaling the cellular machinery (45). Because the overproduced GPX1 activity diminished islet ROS, oxidative inhibition of PTPs including PTP-1B by H₂O₂ was presumably lifted. Knockout of *Ptp-1b* increased phosphorylation of insulin receptor in liver and muscle, and enhanced body resistance to high-fat diet-induced weight gain and insulin resistance (25). Similar enhancements in the *Gpx1*^{-/-} mice were correlated with increased oxidation of the PTP family member phosphatidylinositol 3-kinase-phosphatase with tensin homology in muscle that terminates signals generated by phosphatidylinositol-3-kinase (86). An enhanced AKT signaling in muscle of these mice also helped promote glucose uptake. Both improvements were reversed by antioxidant *N*-acetylcysteine. While increased phosphorylation of AKT and insulin receptor in the *Sod1*^{-/-} mice might additively help improve insulin sensitivity, upregulation of only AKT phosphorylation in the *Gpx1*^{-/-} mice did not produce a significant effect on this function.

Being highly responsive to oxidative stress, JNK is phosphorylated in diabetic conditions, leading to inhibition of insulin gene expression (58). Activation of JNK increased phosphorylation of insulin receptor substrate-1 (IRS-1) on Ser³⁰⁷ that disrupted the interaction between the catalytic domain of the insulin receptor and the phosphotyrosine binding domain of IRS-1 (1, 2). Thus, ablation of *Jnk* increased mouse insulin sensitivity (47). Because downregulation of JNK in the OE mice did not result in improved insulin sensitivity (136), the insulin resistance-inducing factors in OE mice might be too strong to offset. Meanwhile, positive effects of *Sod1* overexpression in liver of *db/db* mice were attributed to decreased expression of phosphoenol-pyruvate carboxykinase and peroxisome proliferator-activated receptor gamma coactivator-1 α , two main regulators of gluconeogenic genes (72). Improved insulin sensitivity in these transgenic mice over their controls was mediated in part by attenuating phosphorylation of cAMP-responsive element-binding protein and JNK.

FIG. 4. Symmetric phenotypes of pancreatic islet β cells and body insulin produced by overexpression of *Gpx1* and knockout of *Gpx1* and *Sod1* each alone or together. The three inside circles represent different status of oxidants/antioxidants: balanced in wild type; reductive stress in the transgenic model; oxidative stress in the knockout models.

FIG. 5. Metabolic role, physiological importance, and molecular mechanism of antioxidant enzymes for different target functions under various ROS status. +, Protection or positive role; -, negative role; ?, questionable role. PTEN, phosphatidylinositol 3-kinase-phosphatase with tensin homology.

Closing Remarks

Although OE and knockouts of *Gpx1* and/or *Sod1* produced nearly symmetric β cell and insulin phenotypes (Fig. 4), physiological roles of antioxidant enzymes in β cells and diabetes are undoubtedly complex. Actual outcome of altering a given enzyme depends on body or tissue ROS status and selected function target (Fig. 5). When ROS is high, such as in overt diabetes, antioxidant enzymes protect β cells against hyperglycemia-induced oxidative destructions of macromolecules. These enzymes also help prevent oxidative inhibitions of key transcriptional factors like PDX1 and thus maintain β cell mass and function. However, overly diminishing intracellular ROS by excessively high antioxidant enzyme activities dys-regulates GSIS or insulin signaling. Overall, we should not overlook metabolic difference or subtlety between overexpression and knockout of a given antioxidant enzyme, mitochondrial and cytosolic locations, hydroperoxide and superoxide scavenging functions, and pro-oxidants- and cytokines-induced ROS. Apparently, acute effects of antioxidant enzymes on bolus of ROS may be different from their chronic effects on metabolically generated endogenous ROS. A good example is the above-discussed lack of protection of antioxidant enzyme overexpression against cytokine toxicity in β cells or islets. Likewise, a transient benefit may even evolve into a metabolic disorder in a long run. Experimentally, the OE mice may be used as a new model to study role of antioxidant enzymes in insulin resistance, type 2 diabetes, and obesity. Meanwhile, the *Sod1*^{-/-} mice may offer a novel model to study antioxidant enzymes in type 1 diabetes and pancreatitis (Fig. 3). Technically, animal models with tissue specific knockouts or tissue-specific overexpression (in addition to β cell-specific) of antioxidant enzymes should be generated to fully elucidate specific mechanisms for their metabolic roles in β cells and diabetes.

Acknowledgment

Research in the authors' laboratory was supported in part by DK53018 (XGL).

References

1. Aguirre V, Uchida T, Yenush L, Davis R, and White MF. The c-Jun NH2-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser307. *J Biol Chem* 275: 9047-9054, 2000.
2. Aguirre V, Werner ED, Giraud J, Lee YH, Shoelson SE, and White MF. Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action. *J Biol Chem* 277: 1531-1537, 2002.
3. Ahlgren U, Jonsson J, Jonsson L, Simu K, and Edlund H. Beta cell-specific inactivation of the mouse *Ipf1/Pdx1* gene results in loss of the beta-cell phenotype and maturity onset diabetes. *Genes Dev* 12: 1763-1768, 1998.
4. Ahren B. Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes. *Nat Rev Drug Discov* 8: 369-385, 2009.
5. Archuleta TL, Lemieux AM, Saengsirisuwan V, Teachey MK, Lindborg KA, Kim JS, and Henriksen EJ. Oxidant stress-induced loss of IRS-1 and IRS-2 proteins in rat skeletal muscle: role of p38 MAPK. *Free Radic Biol Med* 47: 1486-1493, 2009.
6. Asayama K, Kooy N, and Burr I. Effect of vitamin E deficiency and selenium deficiency on insulin secretory reserve and free radical scavenging systems in islets: decrease of islet manganosuperoxide dismutase. *J Lab Clin Med* 107: 459-464, 1986.
7. Bertera S, Crawford ML, Alexander AM, Papworth GD, Watkins SC, Robbins PD, and Trucco M. Gene transfer of manganese superoxide dismutase extends islet graft function in a mouse model of autoimmune diabetes. *Diabetes* 52: 387-393, 2003.
8. Blair AS, Hajdich E, Litherland GJ, and Hundal HS. Regulation of glucose transport and glycogen synthesis in I6 muscle cells during oxidative stress. *J Biol Chem* 274: 36293-36299, 1999.
9. Bleys J, Navas-Acien A, and Guallar E. Selenium and diabetes: more bad news for supplements. *Ann Intern Med* 147: 271-272, 2007.

10. Bleys J, Navas-Acien A, Stranges S, Menke A, Miller ER III, and Guallar E. Serum selenium and serum lipids in US adults. *Am J Clin Nutr* 88: 416–423, 2008.
11. Bochkis IM, Rubins NE, White P, Furth EE, Friedman JR, and Kaestner KH. Hepatocyte-specific ablation of Foxa2 alters bile acid homeostasis and results in endoplasmic reticulum stress. *Nat Med* 14: 828–836, 2008.
12. Boucher M-J, Selander L, Carlsson L, and Edlund H. Phosphorylation marks IPF1/PDX1 protein for degradation by glycogen synthase kinase 3-dependent mechanisms. *J Biol Chem* 281: 6395–6403, 2006.
13. Butler AE, Janson J, Soeller WC, and Butler PC. Increased beta-cell apoptosis prevents adaptive increase in beta-cell mass in mouse model of type 2 diabetes: evidence for role of islet amyloid formation rather than direct action of amyloid. *Diabetes* 52: 2304–2314, 2003.
14. Carroll JS, Liu XS, Brodsky AS, Li W, Meyer CA, Szary AJ, Eeckhoutte J, Shao W, Hestermann EV, Geistlinger TR, Fox EA, Silver PA, and Brown M. Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. *Cell* 122: 33–43, 2005.
15. Ceriello A. Oxidative stress and glycemic regulation. *Metabolism* 49: 27–29, 2000.
16. Chen H, Carlson EC, Pellet L, Moritz JT, and Epstein PN. Overexpression of metallothionein in pancreatic beta-cells reduces streptozotocin-induced DNA damage and diabetes. *Diabetes* 50: 2040–2046, 2001.
17. Chen H, Li X, and Epstein PN. MnSOD and catalase transgenes demonstrate that protection of islets from oxidative stress does not alter cytokine toxicity. *Diabetes* 54: 1437–1446, 2005.
18. Chen X, Scholl TO, Leskiw MJ, Donaldson MR, and Stein TP. Association of glutathione peroxidase activity with insulin resistance and dietary fat intake during normal pregnancy. *J Clin Endocrinol Metab* 88: 5963–5968, 2003.
19. Cheng W-H, Ho Y-S, Ross DA, Han Y, Combs GF Jr., and Lei XG. Overexpression of cellular glutathione peroxidase does not affect expression of plasma glutathione peroxidase or phospholipid hydroperoxide glutathione peroxidase in mice offered diets adequate or deficient in selenium. *J Nutr* 127: 675–680, 1997.
20. Cheng W-H, Ho Y-S, Valentine BA, Ross DA, Combs GF Jr., and Lei XG. Cellular glutathione peroxidase is the mediator of body selenium to protect against paraquat lethality in transgenic mice. *J Nutr* 128: 1070–1076, 1998.
21. Chou FC and Sytwu, HK. Overexpression of thioredoxin in islets transduced by a lentiviral vector prolongs graft survival in autoimmune diabetic NOD mice. *J Biomed Sci* 16: 71, 2009.
22. Chung SS, Kim M, Youn B-S, Lee NS, Park JW, Lee IK, Lee YS, Kim JB, Cho YM, Lee HK, and Park KS. Glutathione peroxidase 3 mediates the antioxidant effect of peroxisome proliferator-activated receptor-gamma in human skeletal muscle cells. *Mol Cell Biol* 29: 20–30, 2009.
23. Czernichow S, Couthouis A, Bertrais S, Vergnaud A-C, Dauchet L, Galan P, and Hercberg S. Antioxidant supplementation does not affect fasting plasma glucose in the supplementation with antioxidant vitamins and minerals (SU.VI.MAX) study in France: association with dietary intake and plasma concentrations. *Am J Clin Nutr* 84: 395–399, 2006.
24. Eberharther A and Becker P. Histone acetylation: a switch between repressive and permissive chromatin. Second in review series on chromatin dynamics. *EMBO Rep* 3: 224–229, 2002.
25. Elchebly M, Payette P, Michaliszyn E, Cromlish W, Collins S, Loy AL, Normandin D, Cheng A, Himms-Hagen J, Chan C-C, Ramachandran C, Gresser MJ, Tremblay ML, and Kennedy BP. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1b gene. *Science* 283: 1544–1548, 1999.
26. Esposito LA, Kokoszka JE, Waymire KG, Cottrell B, MacGregor GR, and Wallace DC. Mitochondrial oxidative stress in mice lacking the glutathione peroxidase-1 gene. *Free Radic Biol Med* 28: 754–766, 2000.
27. Evans J and Goldfine I. Alpha-lipoic acid: a multifunctional antioxidant that improves insulin sensitivity in patients with type 2 diabetes. *Diabetes Technol Ther* 2: 401–413, 2000.
28. Evans JL, Goldfine ID, Maddux BA, and Grodsky GM. Are oxidative stress-activated signaling pathways mediators of insulin resistance and beta-cell dysfunction? *Diabetes* 52: 1–8, 2003.
29. Feanny MA, Fagan SP, Ballian N, Liu S-H, Li Z, Wang X, Fisher W, Brunicardi FC, and Belaguli NS. PDX-1 expression is associated with islet proliferation *in vitro* and *in vivo*. *J Surg Res* 144: 8–16, 2008.
30. Federici M, Hribal M, Perego L, Ranalli M, Caradonna Z, Perego C, Usellini L, Nano R, Bonini P, Bertuzzi F, Marlier LN, Davalli AM, Carandente O, Pontiroli AE, Melino G, Marchetti P, Lauro R, Sesti G, and Folli F. High glucose causes apoptosis in cultured human pancreatic islets of langerhans: a potential role for regulation of specific bcl family genes toward an apoptotic cell death program. *Diabetes* 50: 1290–1301, 2001.
31. Feltus F, Lee E, Costello J, Plass C, Vertino PM. Predicting aberrant CpG island methylation. *Proc Natl Acad Sci USA* 100: 12253–12258, 2003.
32. Fernandez AM, Kim JK, Yakar S, Dupont JL, Hernandez-Sanchez C, Castle AL, Filmore J, Shulman GI, and Le Roith D. Functional inactivation of the IGF-I and insulin receptors in skeletal muscle causes type 2 diabetes. *Genes Dev* 15: 1926–1934, 2001.
33. Flekac M, Skrha J, Hilgertova J, Lacinova Z, and Jarolimkova M. Gene polymorphisms of superoxide dismutases and catalase in diabetes mellitus. *BMC Med Genet* 9: 30–35, 2008.
34. Fu Y, Cheng W-H, Porres JM, Ross DA, and Lei XG. Knockout of cellular glutathione peroxidase gene renders mice susceptible to diquat-induced oxidative stress. *Free Radic Biol Med* 27: 605–611, 1999.
35. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Nakayama O, Makishima M, Matsuda M, and Shimomura I. Increased oxidative stress in obesity and its impact on metabolic syndrome. *J Clin Invest* 114: 1752–1761, 2004.
36. Gao N, LeLay J, Vatamaniuk MZ, Rieck S, Friedman JR, and Kaestner KH. Dynamic regulation of Pdx1 enhancers by Foxa1 and Foxa2 is essential for pancreas development. *Genes Dev* 15: 3435–3448, 2008.
37. Gao N, White P, Doliba N, Golson ML, Matschinsky FM, and Kaestner KH. Foxa2 controls vesicle docking and insulin secretion in mature beta-cells. *Cell Metab* 6: 267–279, 2007.
38. Gimeno R, Dembski M, Weng X, Deng N, Shyjan A, Gimeno C, Iris F, Ellis S, Woolf E, and Tartaglia L. Cloning

- and characterization of an uncoupling protein homolog: a potential molecular mediator of human thermogenesis. *Diabetes* 46: 900–906, 1997.
39. Goldstein BJ, Mahadev K, and Wu X. Redox paradox: insulin action is facilitated by insulin-stimulated reactive oxygen species with multiple potential signaling targets. *Diabetes* 54: 311–321, 2005.
 40. Grankvist K, Marklund S, and Täljedal I. CuZn-superoxide dismutase, Mn-superoxide dismutase, catalase and glutathione peroxidase in pancreatic islets and other tissues in the mouse. *Biochem J* 199: 393–398, 1981.
 41. Gupta RK, Vatamaniuk MZ, Lee CS, Flaschen RC, Fulmer JT, Matschinsky FM, Duncan SA, and Kaestner KH. The MODY1 gene HNF4 α regulates selected genes involved in insulin secretion. *J Clin Invest* 115: 1006–1015, 2005.
 42. Gurgul E, Lortz S, Tiedge M, Jorns A, and Lenzen S. Mitochondrial catalase overexpression protects insulin-producing cells against toxicity of reactive oxygen species and proinflammatory cytokines. *Diabetes* 53: 2271–2280, 2004.
 43. Harmon JS, Bogdani M, Parazzoli SD, Mak SSM, Oseid EA, Berghmans M, LeBoeuf RC, and Robertson RP. Beta-cell-specific overexpression of glutathione peroxidase preserves intranuclear mafa and reverses diabetes in db/db mice. *Endocrinology* 150: 4855–4862, 2009.
 44. Hashizume K, Hirasawa M, Imamura Y, Noda S, Shimizu T, Shinoda K, Kurihara T, Noda K, Ozawa Y, Ishida S, Miyake Y, Shirasawa T, and Tsubota K. Retinal dysfunction and progressive retinal cell death in SOD1-deficient mice. *Am J Pathol* 172: 1325–1331, 2008.
 45. Hayes G and Lockwood D. Role of insulin receptor phosphorylation in the insulinomimetic effects of hydrogen peroxide. *Proc Natl Acad Sci USA* 84: 8115–8119, 1987.
 46. Hirashima O, Kawano H, Motoyama T, Hirai N, Ohgushi M, Kugiyama K, Ogawa H, and Yasue H. Improvement of endothelial function and insulin sensitivity with vitamin C in patients with coronary spastic angina: possible role of reactive oxygen species. *J Am Coll Cardiol* 35: 1860–1866, 2000.
 47. Hirosumi J, Tuncman G, Chang L, Gorgun CZ, Uysal KT, Maeda K, Karin M, and Hotamisligil GS. A central role for JNK in obesity and insulin resistance. *Nature* 420: 333–336, 2002.
 48. Hogan C and Varga-Weisz P. The regulation of ATP-dependent nucleosome remodelling factors. *Mut Res Fundam Mol Mech Mutagen* 618: 41–51, 2007.
 49. Holland AM, Gonez LJ, Naselli G, MacDonald RJ, and Harrison LC. Conditional expression demonstrates the role of the homeodomain transcription factor pdx1 in maintenance and regeneration of beta-cells in the adult pancreas. *Diabetes* 54: 2586–2595, 2005.
 50. Houstis N, Rosen ED, and Lander ES. Reactive oxygen species have a causal role in multiple forms of insulin resistance. *Nature* 440: 944–948, 2006.
 51. Hui H and Perfetti R. Pancreas duodenum homeobox-1 regulates pancreas development during embryogenesis and islet cell function in adulthood. *Eur J Endocrinol* 146: 129–141, 2002.
 52. Jacob S, Ruus P, Hermann R, Tritschler HJ, Maerker E, Renn W, Augustin HJ, Dietze GJ, and Rett K. Oral administration of rac- α -lipoic acid modulates insulin sensitivity in patients with type-2 diabetes mellitus: a placebo-controlled pilot trial. *Free Radic Biol Med* 27: 309–314, 1999.
 53. Johnson J, Bernal-Mizrachi E, Alejandro E, Han Z, Kalyaniak T, Li H, Beith J, Gross J, Warnock G, Townsend R, Permutt M, and Polonsky KS. Insulin protects islets from apoptosis via Pdx1 and specific changes in the human islet proteome. *Proc Natl Acad Sci USA* 103: 19575–19580, 2006.
 54. Johnson JD, Ahmed NT, Luciani DS, Han Z, Tran H, Fujita J, Misler S, Edlund H, and Polonsky KS. Increased islet apoptosis in Pdx1^{+/-} mice. *J Clin Invest* 111: 1147–1160, 2003.
 55. Johnson M, Heineke E, Rhinehart B, Sheetz M, Barnhart R, and Robinson K. MDL 29311. Antioxidant with marked lipid- and glucose-lowering activity in diabetic rats and mice. *Diabetes* 42: 1179–1186, 1993.
 56. Jonsson J, Carlsson L, Edlund T, and Edlund H. Insulin-promoter-factor 1 is required for pancreas development in mice. *Nature* 371: 606–609, 1994.
 57. Kaestner KH, Knochel W, and Martinez DE. Unified nomenclature for the winged helix/forkhead transcription factors. *Genes Dev* 14: 142–146, 2000.
 58. Kajimoto Y and Kaneto H. Role of oxidative stress in pancreatic beta-cell dysfunction. *Ann NY Acad Sci* 1011: 168–176, 2004.
 59. Kaneto H, Kajimoto Y, Miyagawa J, Matsuoka T, Fujitani Y, Umayahara Y, Hanafusa T, Matsuzawa Y, Yamasaki Y, and Hori M. Beneficial effects of antioxidants in diabetes: possible protection of pancreatic beta-cells against glucose toxicity. *Diabetes* 48: 2398–2406, 1999.
 60. Kaneto H, Kawamori D, Nakatani Y, Gorogawa S, and Matsuoka TA. Oxidative stress and the JNK pathway as a potential therapeutic target for diabetes. *Drug News Perspect* 17: 447–453, 2004.
 61. Kaneto H, Miyatsuka T, Kawamori D, Yamamoto K, Kato K, Shiraiwa T, Katakami N, Yamasaki Y, Matsuhisa M, and Matsuoka T. PDX-1 and MafA play a crucial role in pancreatic beta-cell differentiation and maintenance of mature beta-cell function. *Endocr J* 55: 235–252, 2008.
 62. Katsuki A, Sumida Y, Urakawa H, Gabazza EC, Mura-shima S, Nakatani K, Yano Y, and Adachi Y. Increased oxidative stress is associated with serum levels of triglyceride, insulin resistance, and hyperinsulinemia in Japanese metabolically obese, normal-weight men. *Diabetes Care* 27: 631–632, 2004.
 63. Kawamori D, Kajimoto Y, Kaneto H, Umayahara Y, Fujitani Y, Miyatsuka T, Watada H, Leibiger IB, Yamasaki Y, and Hori M. Oxidative stress induces nucleo-cytoplasmic translocation of pancreatic transcription factor Pdx-1 through activation of c-Jun NH2-terminal kinase. *Diabetes* 52: 2896–2904, 2003.
 64. Kawamori D, Kaneto H, Nakatani Y, Matsuoka TA, Matsuhisa M, Hori M, and Yamasaki Y. The forkhead transcription factor foxo1 bridges the jnk pathway and the transcription factor pdx-1 through its intracellular translocation. *J Biol Chem* 281: 1091–1098, 2006.
 65. Keller DM, McWeeney S, Arsenlis A, Drouin J, Wright CVE, Wang H, Wollheim CB, White P, Kaestner KH, and Goodman RH. Characterization of pancreatic transcription factor pdx-1 binding sites using promoter microarray and serial analysis of chromatin occupancy. *J Biol Chem* 282: 32084–32092, 2007.
 66. Kikumoto Y, Sugiyama H, Inoue T, Morinaga H, Takiue K, Kitagawa M, Fukuoka N, Saeki M, Maeshima Y, Wang D-H, Ogino K, Matsuoka N, and Makino H. Sensitization to alloxan-induced diabetes and pancreatic cell apoptosis in acatalasemic mice. *Biochim Biophys Acta Mol Basis Dis* 1802: 240–246, 2010.

67. Kitamura T and Ido Kitamura Y. Proteins in pancreatic beta cells. *Endocr J* 54: 507–515, 2007.
68. Kitamura T, Nakae J, Kitamura Y, Kido Y, Biggs WH 3rd, Wright CV, White MF, Arden KC, and Accili D. The forkhead transcription factor Foxo1 links insulin signaling to Pdx1 regulation of pancreatic beta-cell growth. *J Clin Invest* 110: 1839–1847, 2002.
69. Krauss S, Zhang C-Y, Scorrano L, Dalgaard LT, St-Pierre J, Grey ST, and Lowell BB. Superoxide-mediated activation of uncoupling protein 2 causes pancreatic beta cell dysfunction. *J Clin Invest* 112: 1831–1842, 2003.
70. Kubisch H, Wang J, Bray T, and Phillips J. Targeted overexpression of Cu/Zn superoxide dismutase protects pancreatic beta-cells against oxidative stress. *Diabetes* 46: 1563–1566, 1997.
71. Kubisch H, Wang J, Luche R, Carlson E, Bray T, Epstein C, and Phillips J. Transgenic copper/zinc superoxide dismutase modulates susceptibility to type I diabetes. *Proc Natl Acad Sci USA* 91: 9956–9959, 1994.
72. Kumashiro N, Tamura Y, Uchida T, Ogihara T, Fujitani Y, Hirose T, Mochizuki H, Kawamori R, and Watada H. Impact of oxidative stress and peroxisome proliferator-activated receptor gamma coactivator-1 alpha in hepatic insulin resistance. *Diabetes* 57: 2083–2091, 2008.
73. Kushner JA, Haj FG, Klamon LD, Dow MA, Kahn BB, Neel BG, and White MF. Islet-sparing effects of protein tyrosine phosphatase-1b deficiency delays onset of diabetes in irs2 knockout mice. *Diabetes* 53: 61–66, 2004.
74. Kuzuya M, Ando F, Iguchi A, and Shimokata H. Glutathione peroxidase 1 Pro198Leu variant contributes to the metabolic syndrome in men in a large Japanese cohort. *Am J Clin Nutr* 87: 1939–1944, 2008.
75. Laclaustra M, Navas-Acien A, Stranges S, Ordovas JM, and Guallar E. Serum selenium concentrations and hypertension in the us population. *Circ Cardiovasc Qual Outcomes* 2: 369–376, 2009.
76. Laclaustra M, Stranges S, Navas-Acien A, Ordovas JM, and Guallar E. Serum selenium and serum lipids in US adults: National Health and Nutrition Examination Survey (NHANES) 2003–2004. *Atherosclerosis* 210: 643–648, 2010.
77. Lee CS, Sund NJ, Vatamaniuk MZ, Matschinsky FM, Stoffers DA, and Kaestner KH. Foxa2 controls pdx1 gene expression in pancreatic beta cells *in vivo*. *Diabetes* 51: 2546–2551, 2002.
78. Lee DY, Hayes JJ, Pruss D, and Wolffe AP. A positive role for histone acetylation in transcription factor access to nucleosomal DNA. *Cell* 72: 73–84, 1993.
79. Leloup C, Tourrel-Cuzin CC, Magnan C, Karaca M, Castel J, Carneiro L, Colombani A-L, Ktorza A, Casteilla L, and Pénicaud L. Mitochondrial reactive oxygen species are obligatory signals for glucose-induced insulin secretion. *Diabetes* 58: 673–681, 2009.
80. Lenzen S, Drinkgern J, and Tiedge M. Low antioxidant enzyme gene expression in pancreatic islets compared with various other mouse tissues. *Free Radic Biol Med* 20: 463–466, 1996.
81. Leonard J, Peers B, Johnson T, Ferreri K, Lee S, and Montminy MR. Characterization of somatostatin transactivating factor-1, a novel homeobox factor that stimulates somatostatin expression in pancreatic islet cells. *Mol Endocrinol* 7: 1275–1283, 1993.
82. Lepore DA, Shinkel TA, Fisicaro N, Mysore TB, Johnson LEA, d'Apice AJF, and Cowan PJ. Enhanced expression of glutathione peroxidase protects islet β cells from hypoxia-reoxygenation. *Xenotransplantation* 11: 53–59, 2004.
83. Li X, Chen H, and Epstein PN. Metallothionein and catalase sensitize to diabetes in nonobese diabetic mice: reactive oxygen species may have a protective role in pancreatic beta-cells. *Diabetes* 55: 1592–1604, 2006.
84. Like A and Rossini A. Streptozotocin-induced pancreatic insulinitis: new model of diabetes mellitus. *Science* 193: 415–417, 1976.
85. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD III, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, Meyskens FL Jr., Baker LH, and Coltman CA Jr. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the selenium and vitamin e cancer prevention trial (SELECT). *JAMA* 301: 39–51, 2009.
86. Loh K, Deng H, Fukushima A, Cai X, Boivin B, Galic S, Bruce C, Shields BJ, Skiba B, Ooms LM, Stepto N, Wu B, Mitchell CA, Tonks NK, Watt MJ, Febbraio MA, Crack PJ, Andrikopoulos S, and Tiganis T. Reactive oxygen species enhance insulin sensitivity. *Cell Metab* 10: 260–272, 2009.
87. Lortz S, Gurgul-Convey E, Lenzen S, and Tiedge M. Importance of mitochondrial superoxide dismutase expression in insulin-producing cells for the toxicity of reactive oxygen species and proinflammatory cytokines. *Diabetologia* 48: 1541–1548, 2005.
88. Lortz S and Tiedge M. Sequential inactivation of reactive oxygen species by combined overexpression of SOD isoforms and catalase in insulin-producing cells. *Free Radic Biol Med* 34: 683–688, 2003.
89. Lortz S, Tiedge M, Nachtwey T, Karlsen AE, Nerup J, and Lenzen S. Protection of insulin-producing RINm5F cells against cytokine-mediated toxicity through overexpression of antioxidant enzymes. *Diabetes* 49: 1123–1130, 2000.
90. Lu H, Koshkin V, Allister EM, Gyulhandanyan AV, and Wheeler MB. Molecular and metabolic evidence for mitochondrial defects associated with β -cell dysfunction in a mouse model of type 2 diabetes. *Diabetes* 59: 448–459, 2010.
91. Maechler P, Jornot L, and Wollheim CB. Hydrogen peroxide alters mitochondrial activation and insulin secretion in pancreatic beta cells. *J Biol Chem* 274: 27905–27913, 1999.
92. Martens GA, Cai Y, Hinke S, Stangé G, Van de Castele M, and Pipeleers D. Glucose suppresses superoxide generation in metabolically responsive pancreatic beta-cells. *J Biol Chem* 280: 20389–20386, 2005.
93. McClung JP, Roneker CA, Mu W, Lisk DJ, Langlais P, Liu F, and Lei XG. Development of insulin resistance and obesity in mice overexpressing cellular glutathione peroxidase. *Proc Natl Acad Sci USA* 101: 8852–8857, 2004.
94. Meng T-C, Buckley DA, Galic S, Tiganis T, and Tonks NK. Regulation of insulin signaling through reversible oxidation of the protein-tyrosine phosphatases TC45 and PTP1B. *J Biol Chem* 279: 37716–37725, 2004.
95. Mirochnitchenko O, Weisbrodt-Lefkowitz M, Reuhl K, Chen L, Yang C, and Inouye M. Acetaminophen Toxicity. Opposite effects of two forms of glutathione peroxidase. *J Biol Chem* 274: 10349–10355, 1999.
96. Mitchell P. Coupling of phosphorylation to electron and hydrogen transfer by a chemi-osmotic type of mechanism. *Nature* 8: 144–148, 1961.
97. Moriscot C, Richard M, Favrot M, and Benhamou P. Protection of insulin-secreting Ins-1 cells against oxidative

- stress through adenoviral-mediated glutathione peroxidase overexpression. *Diabetes Metab* 29: 145–151, 2003.
98. Mueller AS, Mueller K, Wolf NM, and Pallauf J. Selenium and diabetes: an enigma? *Free Radic Res* 43: 1029–1059, 2009.
 99. Mysore TB, Shinkel TA, Collins J, Salvaris EJ, Fisicaro N, Murray-Segal LJ, Johnson LEA, Lepore DA, Walters SN, Stokes R, Chandra AP, O'Connell PJ, d'Apice AJF, and Cowan PJ. Overexpression of glutathione peroxidase with two isoforms of superoxide dismutase protects mouse islets from oxidative injury and improves islet graft function. *Diabetes* 54: 2109–2116, 2005.
 100. Negre-Salvayre A, Hirtz C, Carrera G, Cazenave R, Trolly M, Salvayre R, Penicaud L, and Casteilla L. A role for uncoupling protein-2 as a regulator of mitochondrial hydrogen peroxide generation. *FASEB J* 11: 809–815, 1997.
 101. Norton VG, Marvin KW, Yau P, and Bradbury EM. Nucleosome linking number change controlled by acetylation of histones H3 and H4. *J Biol Chem* 265: 19848–19852, 1990.
 102. Ohkuwa T, Sato Y, and Naoi M. Hydroxyl radical formation in diabetic rats induced by streptozotocin. *Life Sci* 56: 1789–1798, 1995.
 103. Ohlsson H, Karlsson K, and Edlund T. IPF1, a homeodomain-containing transactivator of the insulin gene. *EMBO J* 12: 4251–4259, 1993.
 104. Olofsson EM, Marklund SL, and Behndig A. Glucose-induced cataract in CuZn-SOD null lenses: an effect of nitric oxide? *Free Radic Biol Med* 42: 1098–1105, 2007.
 105. Panowski SH, Wolff S, Aguilaniu H, Durieux J, and Dillin A. PHA-4/Foxa mediates diet-restriction-induced longevity of *C. elegans*. *Nature* 447: 550–555, 2007.
 106. Park J, Stoffers D, Nicholls R, and Simmons R. Development of type 2 diabetes following intrauterine growth retardation in rats is associated with progressive epigenetic silencing of Pdx1. *J Clin Invest* 118: 2316–2324, 2008.
 107. Peshavaria M, Larmie BL, Lausier J, Satish B, Habibovic A, Roskens V, LaRock K, Everill B, Leahy JL, and Jetton TL. Regulation of pancreatic beta-cell regeneration in the normoglycemic 60% partial-pancreatectomy mouse. *Diabetes* 55: 3289–3298, 2006.
 108. Pi J, Bai Y, Zhang Q, Wong V, Floering LM, Daniel K, Reece JM, Deeney JT, Andersen ME, Corkey BE, and Collins S. Reactive oxygen species as a signal in glucose-stimulated insulin secretion. *Diabetes* 56: 1783–1791, 2007.
 109. Rhodes C. Type 2 diabetes—a matter of beta-cell life and death? *Science* 307: 380–384, 2005.
 110. Ristow M, Zarse K, Oberbach A, Kloting N, Birringer M, Kiehnopf M, Stumvoll M, Kahn CR, and Bluher M. Antioxidants prevent health-promoting effects of physical exercise in humans. *Proc Natl Acad Sci USA* 106: 8665–8670, 2009.
 111. Robbins MJ, Sharp RA, Slonim AE, and Burr IM. Protection against streptozotocin-induced diabetes by superoxide dismutase. *Diabetologia* 18: 55–58, 1980.
 112. Robertson R. Chronic oxidative stress as a central mechanism for glucose toxicity in pancreatic islet beta-cells in diabetes. *J Biol Chem* 279: 42351–42354, 2004.
 113. Robertson RP, Tanaka Y, Takahashi H, Tran POT, and Harmon JS. Prevention of oxidative stress by adenoviral overexpression of glutathione-related enzymes in pancreatic islets. *Ann NY Acad Sci* 1043: 513–520, 2005.
 114. Rudich A, Kozlovsky N, Potashnik R, and Bashan N. Oxidant stress reduces insulin responsiveness in 3T3-L1 adipocytes. *Am J Physiol Endocrinol Metab* 272: E935–E940, 1997.
 115. Sandstrom J, Jonsson LM, Edlund H, Holmberg D, and Marklund SL. Overexpression of extracellular-SOD in islets of nonobese diabetic mice and development of diabetes. *Free Radic Biol Med* 33: 71–75, 2002.
 116. Sharma A, Zangen DH, Reitz P, Taneja M, Lissauer ME, Miller CP, Weir GC, Habener JF, and Bonner-Weir S. The homeodomain protein IDX-1 increases after an early burst of proliferation during pancreatic regeneration. *Diabetes* 48: 507–513, 1999.
 117. Sharma S, Leonard J, Lee S, Chapman HD, Leiter EH, and Montminy MR. Pancreatic islet expression of the homeobox factor stf-1 relies on an e-box motif that binds USF. *J Biol Chem* 271: 2294–2299, 1996.
 118. Simmons RA, Suponitsky-Kroyter I, and Selak MA. Progressive accumulation of mitochondrial DNA mutations and decline in mitochondrial function lead to beta-cell failure. *J Biol Chem* 280: 28785–28791, 2005.
 119. Stoffers D. The development of beta-cell mass: recent progress and potential role of Glp-1. *Horm Metab Res* 36: 811–821, 2004.
 120. Stoffers D, Ferrer J, Clarke WH, and Habener JF. Early-onset type-2 diabetes mellitus (MODY4) linked to IPF1. *Nat Genet* 17: 138–139, 1997.
 121. Stoffers DA, Stanojevic V, and Habener JF. Insulin promoter factor-1 gene mutation linked to early-onset type 2 diabetes mellitus directs expression of a dominant negative isoprotein. *J Clin Invest* 102: 232–241, 1998.
 122. Stranges S, Laclaustra M, Ji C, Cappuccio FP, Navas-Acien A, Ordovas JM, Rayman M, and Guallar E. Higher selenium status is associated with adverse blood lipid profile in British adults. *J Nutr* 140: 81–87, 2010.
 123. Stranges S, Marshall JR, Natarajan R, Donahue RP, Trevisan M, Combs GF, Cappuccio FP, Ceriello A, and Reid ME. Effects of long-term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. *Ann Intern Med* 147: 217–223, 2007.
 124. Sund NJ, Vatamaniuk MZ, Casey M, Ang S-L, Magnuson MA, Stoffers DA, Matschinsky FM, and Kaestner KH. Tissue-specific deletion of Foxa2 in pancreatic beta-cells results in hyperinsulinemic hypoglycemia. *Genes Dev* 15: 1706–1715, 2001.
 125. Sunde R. Intracellular glutathione peroxidase—structures, regulation, and functions. In: *Selenium in Biology and Human Health*, edited by Burk RF. New York: Springer-Verlag, 1994, pp. 45–77.
 126. Takasu N, Asawa T, Komiya I, Nagasawa Y, and Yamada T. Alloxan-induced DNA strand breaks in pancreatic islets. Evidence for H₂O₂ as an intermediate. *J Biol Chem* 266: 2112–2114, 1991.
 127. Tanaka Y, Tran POT, Harmon J, and Robertson RP. A role for glutathione peroxidase in protecting pancreatic beta-cells against oxidative stress in a model of glucose toxicity. *Proc Natl Acad Sci USA* 99: 12363–12368, 2002.
 128. Tazi J and Bird A. Alternative chromatin structure at CpG islands. *Cell* 60: 909–920, 1990.
 129. Thorens B, Guillaum M-T, Beermann F, Burcelin R, and Jaquet M. Transgenic reexpression of Glut1 or Glut2 in pancreatic beta cells rescues Glut2-null mice from early death and restores normal glucose-stimulated insulin secretion. *J Biol Chem* 275: 23751–23758, 2000.
 130. Tiedge M, Lortz S, Drinkgern J, and Lenzen S. Relation between antioxidant enzyme gene expression and anti-

- oxidative defense status of insulin-producing cells. *Diabetes* 46: 1733–1742, 1997.
131. Tiedge M, Lortz S, Munday R, and Lenzen S. Complementary action of antioxidant enzymes in the protection of bioengineered insulin-producing RINm5F cells against the toxicity of reactive oxygen species. *Diabetes* 47: 1578–1585, 1998.
 132. Uma S and Ishwarlal J. Alpha-lipoic acid supplementation and diabetes. *Nutr Rev* 66: 646–657, 2008.
 133. Vettese-Dadey M, Grant P, Hebbes T, Crane-Robinson C, Allis C, and Workman J. Acetylation of histone H4 plays a primary role in enhancing transcription factor binding to nucleosomal DNA *in vitro*. *EMBO J* 15: 2508–2518, 1996.
 134. Wang X, Gillen EA, van der Meulen Marjolein CH, and Lei XG. Knockouts of Se-glutathione peroxidase-1 and Cu,Zn superoxide dismutase exert different impacts on femoral mechanical performance of growing mice. *Mol Nutr Food Res* 52: 1334–1339, 2008.
 135. Wang X, Vatamaniuk MZ, Roneker CA, Pepper MP, Hu LG, Simmons RA, and Lei XG. Knockouts of SOD1 and GPX1 exert different impacts on murine islet function and pancreatic integrity. *Antioxid Redox Signal* 14: 391–401, 2011.
 136. Wang XD, Vatamaniuk MZ, Wang SK, Roneker CA, Simmons RA, and Lei XG. Molecular mechanisms for hyperinsulinaemia induced by overproduction of selenium-dependent glutathione peroxidase-1 in mice. *Diabetologia* 51: 1515–1524, 2008.
 137. Wiederkehr A and Wollheim CB. Minireview: implication of mitochondria in insulin secretion and action. *Endocrinology* 147: 2643–2649, 2006.
 138. Wolfrum C, Asilmaz E, Luca E, Friedman JM, and Stoffel M. Foxa2 regulates lipid metabolism and ketogenesis in the liver during fasting and in diabetes. *Nature* 432: 1027–1032, 2004.
 139. Wu KL, Gannon M, Peshavaria M, Offield MF, Henderson E, Ray M, Marks A, Gamer LW, Wright CV, and Stein R. Hepatocyte nuclear factor 3 beta is involved in pancreatic beta -cell-specific transcription of the pdx-1 gene. *Mol Cell Biol* 17: 6002–6013, 1997.
 140. Wu L, Nicholson W, Knobel SM, Steffner RJ, May JM, Piston DW, and Powers AC. Oxidative stress is a mediator of glucose toxicity in insulin-secreting pancreatic islet cell lines. *J Biol Chem* 279: 12126–12134, 2004.
 141. Xu B, Moritz JT, and Epstein PN. Overexpression of catalase provides partial protection to transgenic mouse beta cells. *Free Radic Biol Med* 27: 830–837, 1999.
 142. Zabihi S, Wentzel P, and Eriksson UJ. Maternal blood glucose levels determine the severity of diabetic embryopathy in mice with different expression of copper-zinc superoxide dismutase (Cu,Zn SOD). *Toxicol Sci* 105: 166–172, 2008.
 143. Zhang C-Y, Baffy G, Perret P, Krauss S, Peroni O, Grujic D, Hagen T, Vidal-Puig AJ, Boss O, and Kim Y-B. Uncoupling protein-2 negatively regulates insulin secretion and is a major link between obesity, beta cell dysfunction, and type 2 diabetes. *Cell* 105: 745–755, 2001.
 144. Zhang L, Rubins NE, Ahima RS, Greenbaum LE, and Kaestner KH. Foxa2 integrates the transcriptional response of the hepatocyte to fasting. *Cell Metabolism* 2: 141–148, 2005.
 145. Zhao L, Guo M, Matsuo T-A, Hagman DK, Parazzoli SD, Poitout V, and Stein R. The islet beta-cell-enriched mafa activator is a key regulator of insulin gene transcription. *J Biol Chem* 280: 11887–11894, 2005.
 146. Zhu J-H, Zhang X, Roneker CA, McClung JP, Zhang S, Thannhauser TW, Ripoll DR, Sun Q, and Lei XG. Role of copper, zinc-superoxide dismutase in catalyzing nitrotyrosine formation in murine liver. *Free Radic Biol Med* 45: 611–618, 2008.

Address correspondence to:
 Prof. Xin Gen Lei
 Department of Animal Science
 Cornell University
 252 Morrison Hall
 Ithaca, NY 14853

E-mail: XL20@cornell.edu

Date of first submission to ARS Central, June 22, 2010; date of acceptance, July 10, 2010.

Abbreviations Used

AKT = protein kinase B
 FOXA1 = forkhead box A1
 FOXA2 = forkhead box A2
 FOXO1 = forkhead box O1
 GPX1 = glutathione peroxidase 1
Gpx1^{-/-} = glutathione peroxidase knockout mice
 GSIS = glucose-stimulated insulin secretion
 IR = insulin receptor
 IRS-1 = insulin receptor substrate-1
 JNK = c-jun terminal kinase
 NOD = nonobese diabetic
 OE = overexpressing GPX1
 PDX1 = pancreatic duodenal homeobox 1
 PTEN = phosphatidylinositol 3-kinase-phosphatase with tensin homology
 PTP = protein tyrosine phosphatase
 PTP-1B = protein tyrosine phosphatase-1B
 RNS = reactive nitrogen species
 ROS = reactive oxygen species
 SOD1 = superoxide dismutase 1
Sod1^{-/-} = superoxide dismutase 1 knockout mice
 STZ = streptozotocin
 UCP2 = uncoupling protein 2
 WT = wild type